MAP2K7 and neoplasm: For patients whose tumors express an oncogenic BRAFV600E/K mutation, treatment with the BRAF inhibitor vemurafenib (or, in more recent practice, a combination of the BRAF inhibitor dabrafenib and MEK inhibitor trametinib) results in dramatic tumor regression.